Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Amazon Explores AI Content Marketplace With Media Publishers 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
CAMBRIDGE, Mass., April 05, 2018 -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, will be participating at the following conferences:
| H.C. Wainwright & Co. Global Life Sciences Conference April 9th at 9:00 a.m. CEST – Monte Carlo, Monaco Leerink Partners’ CNS Day April 18th at 10:00 a.m. EST – New York, NY |
About Wave Life Sciences
Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas. For more information, please visit www.wavelifesciences.com.
Investor Contact:
Jillian Connell
617-949-2981
[email protected]
Media Contact:
Jose Juves
617-949-4708
[email protected]
